Compare Stocks → Special FREE offer on stock hotsheets (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IBIOCVE:ICO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.73-2.3%$0.00$1.02▼$27.80$6.02M-3.513.19 million shs65,607 shsICOiCo TherapeuticsC$0.11C$0.11C$0.02▼C$0.16C$952KN/A3.16 million shs1.31 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-5.85%-11.50%+40.48%+176,999,900.00%+176,999,900.00%ICOiCo Therapeutics0.00%0.00%0.00%0.00%0.00%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBioN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$2.38M2.53N/AN/A$15.15 per share0.11ICOiCo TherapeuticsN/AN/AC$0.01 per share8.75C$0.00 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/AICOiCo TherapeuticsN/A-C$0.01N/A∞N/AN/AN/AN/AN/ALatest IBIO, LCT, ICO, and REDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/AICOiCo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBio0.040.910.91ICOiCo TherapeuticsN/A1.141.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%ICOiCo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIBIOiBio1.12%ICOiCo TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio263.48 million3.45 millionN/AICOiCo TherapeuticsN/A9.07 millionN/ANot OptionableIBIO, LCT, ICO, and REDX HeadlinesSourceHeadlineEnlivex Therapeutics Ltd (ENLV)investing.com - April 17 at 2:28 PMIs Covid still a threat four years on from the first wave?msn.com - April 14 at 2:40 PMCara Delevingne sparks backlash over lack of ‘trigger warning’ after revealing horrifying TV show birthmetro.co.uk - April 14 at 9:40 AMThe next Zelda game should be spin-off without Link – Reader’s Featuremsn.com - April 13 at 12:36 AMMinishoot’ Adventures review – Zelda in a spaceshipmsn.com - April 12 at 2:35 PMX Factor legends Jedward say Louis Walsh ‘took advantage’ of themmsn.com - April 9 at 3:37 PMX Factor star Megan McKenna reveals ‘secret’ pregnancy with first child months after getting engagedmetro.co.uk - April 4 at 7:57 PMX Factor star announces engagement and reveals Simon Cowell’s huge role at weddingmsn.com - March 31 at 6:27 PMX Factor star reveals huge role Simon Cowell is going to play at her weddingmsn.com - March 31 at 1:26 PMX Factor icon announces engagement to boyfriendmsn.com - March 29 at 3:09 PMNew pictures show Cara Delevingne’s fire-ravaged $7,000,000 home in ruinsmsn.com - March 27 at 12:16 AMZelda movie director wants to make a ‘serious’ but ‘whimsical’ filmmsn.com - March 26 at 2:39 AMX Factor legend unrecognisable 14 years after iconic auditionmetro.co.uk - March 23 at 5:16 AMX Factor winner comes out after 7 years of speculation to ‘take back control’metro.co.uk - March 23 at 12:16 AMX Factor winner Matt Terry comes out 7 years after rising to fame on showmsn.com - March 22 at 9:01 AMGrammy-nominated X Factor star finally releasing debut album 16 years onmsn.com - March 17 at 7:20 PMX Factor reject overjoyed as she marries partner – but famous sister is absent amid family feudmsn.com - March 16 at 11:13 PMHeartbroken Cara Delevingne speaks out after terrifying fire ravages homemetro.co.uk - March 15 at 5:09 PMWhat you could be buying at Meghan Markle’s American Riviera Orchardmsn.com - March 15 at 12:09 PMFire ravages Cara Delevingne’s home with one person left injuredmetro.co.uk - March 15 at 12:09 PMSinger says Louis Walsh’s Jedward comments are ‘tip of iceberg of abuse’ on X Factormsn.com - March 14 at 2:18 PMWhat is an ICO (Initial Coin Offering) and How Does it Work?fxempire.com - March 9 at 2:57 PMX Factor runner-up is unrecognisable in jaw-dropping American Idol auditionmsn.com - March 4 at 6:46 PMLeap Year brings unexpected proposals – ready to find out your star sign’s Leap Day forecast?msn.com - February 28 at 10:33 AMNew MarketBeat Followers Over TimeTop HeadlinesASML’s Earnings Could Bring The Stock to New HighsApril 16, 2024 10:20 AMView ASML’s Earnings Could Bring The Stock to New Highs5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackArm Holdings Stock Elevating on AI, Cloud, Automotive TailwindsMarch 26, 2024 9:05 AMView Arm Holdings Stock Elevating on AI, Cloud, Automotive TailwindsGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring Prices5 Trends You Need to Know This QuarterApril 13, 2024 9:16 AMView 5 Trends You Need to Know This QuarterAll Headlines Company DescriptionsiBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.iCo TherapeuticsCVE:ICOiCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.